NUVASIVE INC Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Operating activities:
Consolidated net income (loss)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization
Purchase of in-process research and development
Deferred income taxes
Amortization of non-cash interest
Stock-based compensation
Net loss (gain) on strategic investments
Changes in fair value of contingent consideration
Net loss recognized on change in fair value of derivatives
Net loss from foreign currency adjustment
Reserves on current assets
Other non-cash adjustments
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable
Inventory
Prepaid expenses and other assets
Accounts payable and accrued liabilities
Contingent consideration liabilities
Accrued payroll and related expenses
Litigation liability
Income taxes

Net cash provided by operating activities
Investing activities:
Acquisition of Simplify Medical, net of cash acquired
Other acquisitions and investments
Payment of contingent consideration for Simplify Medical
Acquisitions and investments
Proceeds from other investments
Purchases of intangible assets
Purchases of property and equipment
Purchases of marketable securities
Proceeds from sales and maturities of marketable securities
Proceeds from sales of marketable securities
Proceeds from maturities of marketable securities
Other investing activities
Net cash used in investing activities

Financing activities:
Proceeds from the issuance of common stock
Payment of contingent consideration
Purchase of treasury stock
Proceeds from issuance of convertible debt, net of issuance costs
Proceeds from sale of warrants
Purchases of convertible note hedges
Proceeds from revolving line of credit
Repayments on revolving line of credit
Payments upon settlement of senior convertible notes
Other financing activities
Net cash (used in) provided by financing activities

Effect of exchange rate changes on cash
Increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Issuance of common stock in connection with royalty milestone achievement
Supplemental cash flow information:
Interest paid
Income taxes paid

Comments